You are here

Icahn School of Medicine at Mount Sinai

21 Claremont Avenue
Apt 94
NEW YORK, NY 10029
United States

Acute myeloid leukemia (AML) is an aggressive blood cancer in children. Even with strong chemotherapy and bone marrow transplants, many children relapse, and relapse is often deadly. About one in four children in this high-risk group carries a mutation in a gene called WT1. These patients often respond poorly to treatment and relapse early, but we still do not fully understand why. WT1 normally helps guide healthy blood cell growth. When WT1 is damaged, our research shows that leukemia cells can “rewire” themselves to survive.

Icahn School of Medicine at Mount Sinai

Patients with RUNX1-FPD often acquire secondary mutations that increase the risk of disease progression. It is likely that some of these secondary mutations confer more of a risk than others. This risk may also be modified by other factors, such as infections, medications and lifestyle. Currently, we do not understand well the risk associated with each type of mutation and how to modify it. We do not have ways to interfere early in order to prevent or slow progression of the disease to premalignant or malignant stages.

Mentor Name: Elvin Wagenblast

Icahn School of Medicine at Mount Sinai

Recently, researchers discovered that interaction between a special type of brain cells (neurons) and cancer cells plays a crucial role in the growth and progression of a highly aggressive brainstem tumor in children called diffuse intrinsic pontine glioma (DIPG). The neurons associated with cancer cells contribute to tumor growth through direct electrical communication and signaling with chemicals like neurotransmitters (e.g., glutamate and GABA). While the importance of some neurotransmitters is known, the role of a different neurotransmitter "serotonin" remains unclear.

Icahn School of Medicine at Mount Sinai

Clonal hematopoiesis (CH) occurs when certain blood cells begin to grow abnormally and dominate over others, even in people who are otherwise healthy. This condition becomes more common with age and increases the risk of developing blood cancers. However, for individuals with a rare inherited disorder called RUNX1 familial platelet disorder (RUNX1-FPD), CH can appear at a much younger age. While these early clones are often unstable and less likely to lead to cancer, stable clones become more frequent as patients grow older, increasing their cancer risk.

Acute lymphoblastic leukemia (ALL) is the most common form of childhood leukemia and the leading cause of death in children with cancer. While therapy is often curative, ~10% of children will relapse with recurrent disease and abysmal outcomes. Unfortunately, recent efforts to increase the dose or frequency of standard therapy have failed to prevent relapse. Thus, we have reached the ceiling of efficacy for current therapy and new strategies are needed. Here, we take a novel approach by focusing on HMGA1 proteins as drivers of relapse in leukemia.

Leukemia is the most common cancer in children, accounting for almost 1 out of 3 cancers. Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells and is the leading cause of childhood leukemic mortality. There is a great need to improve the outcome of children who are diagnosed with AML by developing better-targeted treatment options. Although both children and adults are affected by AML, studies indicate that the specific genetic mutations present in childhood and adult leukemia are different.

Pages